Cargando…

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces

The anaplastic lymphoma kinase (ALK) receptor is a membrane-bound tyrosine kinase. The pathogenesis of several cancers is closely related to aberrant forms of ALK or aberrant ALK expression, including ALK fusion proteins, ALK-activated point mutations, and ALK amplification. Clinical applications of...

Descripción completa

Detalles Bibliográficos
Autor principal:	Huang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274813/ https://www.ncbi.nlm.nih.gov/pubmed/30400214 http://dx.doi.org/10.3390/ijms19113448

Ejemplares similares

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma
por: Hu, G, et al.
Publicado: (2017)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
por: Brenner, Annette K., et al.
Publicado: (2021)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
por: Sim, Jongmin, et al.
Publicado: (2018)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

The neuronal receptor tyrosine kinase Alk is a target for longevity
por: Woodling, Nathaniel S., et al.
Publicado: (2020)

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
por: Alshareef, Abdulraheem
Publicado: (2017)

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
por: Villa, Matteo, et al.
Publicado: (2021)

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
por: Zhou, F., et al.
Publicado: (2023)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Proteolytic Cleavage of Receptor Tyrosine Kinases
por: Huang, Hao
Publicado: (2021)

Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Wang, Li, et al.
Publicado: (2021)

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
por: Chuang, Cheng-Hao, et al.
Publicado: (2021)

Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review
por: Chen, Monica F., et al.
Publicado: (2023)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Anaplastic lymphoma receptor tyrosine kinase-negative inflammatory myofibroblastic tumor of triceps brachii: Case report
por: Lee, Kyujo, et al.
Publicado: (2020)

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations
por: Yang, Xiaodan, et al.
Publicado: (2021)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis
por: Wu, Kuan-Li, et al.
Publicado: (2021)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
por: Gridelli, Cesare, et al.
Publicado: (2023)

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
por: Golding, Brandon, et al.
Publicado: (2018)

Anaplastic Lymphoma Kinase Receptor: Possible Involvement in Anorexia Nervosa
por: Dedoni, Simona, et al.
Publicado: (2023)

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
por: Watts, Ellen, et al.
Publicado: (2019)

Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
por: Choi, In Ho, et al.
Publicado: (2015)

Anaplastic Lymphoma Kinase in Cutaneous Malignancies
por: Cao, Severine, et al.
Publicado: (2017)

ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017)

Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
por: Schenk, Erin L.
Publicado: (2023)

Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
por: Song, Zilan, et al.
Publicado: (2015)

The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
por: Gouzi, Jean Y., et al.
Publicado: (2011)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

An insight into lung cancer: A comprehensive review exploring anaplastic lymphoma kinase tyrosine kinase inhibitors and mechanisms of resistance
por: Pătcaş, Adela, et al.
Publicado: (2022)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_armgneunf1chbakk74g6fup3b7